Where does Peter Barrett work?

Peter Barrett is Co-founder & Board Member of Obsidiantx and Partner at Atlas Venture and Board director at Synlogic and Board director at Mnemosyne Pharmaceuticals.

What does Peter Barrett invest in?

Peter Barrett invests in Biotech.

What check size does Peter Barrett write?

Peter Barrett typically writes checks of $500K – $5M.

What companies did Peter Barrett found?

Peter Barrett founded Obsidiantx.

Where did Peter Barrett go to school?

Peter Barrett studied at Northeastern University (Phd, Analytical Chemistry).

Peter Barrett

InvestorFounder

Partner at Atlas Venture · Co-founder & Board Member at Obsidiantx · Board director at Synlogic · Board director at Mnemosyne Pharmaceuticals

Massachusetts

Writes $500K – $5M checks · typically $2M

FoundedObsidiantx

Find your path to Peter

1,081 people in our graph share verified history with Peter — schools, employers, funds. One of them is your warm intro.

Matan RoetunlockedPeter: together at Harvard Business School (2023–2025)

×9Peter: together at Harvard Business School

×2Peter: together at Atlas Venture

About

Peter Barrett has worked at Atlas Venture since 2002, helping create therapeutic and drug discovery platform companies. Before Atlas, he co-founded Celera Genomics, serving as executive vice president and chief business officer, and previously held senior management roles at Applera. He holds a BS in chemistry from Lowell Technological Institute (now UMass Lowell) and a PhD in analytical chemistry from Northeastern University.

Contact· self-published, not guessed

p•••@atlasventure.comreveal

Invests in

Biotech

Co-founder & Board Member at Obsidiantx

Intro paths

→

In turn, Peter can intro founders to Obsidiantx's investors below.

Obsidiantx's investors · 3

Atlas VentureCambridge · $500K – $1M checks TCG CrossoverPalo Alto Vertex Ventures HCSingapore · $500K – $10M checks

Co-founders at Obsidiantx

Tom WandlessScientific Founder

Board director at Synlogic

Intro paths

→

In turn, Peter can intro founders to Synlogic's investors below.

Synlogic's investors · 7

Atlas VentureCambridge · $500K – $1M checks · since 2014 New Enterprise Associates (NEA)Menlo Park · $200K – $40M checks · since 2016 NSG VenturesSingapore OrbiMedNew York · $1M – $75M checks · since 2017 Pfizer Venture Investments$5M – $20M checks Sofinnova VenturesMenlo Park · $100K – $15M checks Solasta VenturesBoston

Board director at Mnemosyne Pharmaceuticals

Intro paths

→

In turn, Peter can intro founders to Mnemosyne Pharmaceuticals's investors below.

Mnemosyne Pharmaceuticals's investors · 2

Atlas VentureCambridge · $500K – $1M checks · since 2012 Clal Biotechnology IndustriesTel Aviv · since 2012

Experience

Atlas VenturePartner
Harvard Business SchoolHarvard Business School Facultycurrent2016 — presentCambridge, Massachusetts, United States
ArchemixBoard Member2002 — 2010
Celera GenomicsExecutive Vice President1998 — 2002
PerkinElmerCorporate Vice Preisdent1979 — 1998

Deals · 1

Antegrin TherapeuticsBoard seat

via Atlas Venture · filed Aug 2017 · $26M raise

Attribution from SEC filings, press coverage, and firm rosters.

Other disclosed investments

Board seats

AlnylamArchemixCadent TherapeuticsHarbour AntibodiesLarimar TherapeuticsMomentaNovamedNucleate BioObsidian TherapeuticsRevvitySirion TherapeuticsStromedixSynlogicVitae Pharmaceuticals

Investor

ArchemixCadent TherapeuticsDeepscaleHarbour AntibodiesIndalo TherapeuticsInfacare PharmaceuticalJenaValve TechnologyLarimar TherapeuticsMomenta PharmaceuticalsObsidian TherapeuticsPosterousRaze TherapeuticsStromedixSynlogic

Sources: the firm's website · SEC Form D filings · curated public sources.

Colleagues at Atlas Venture

Aimee Raleigh

Principal at Atlas Venture

Bruce Booth

Partner at Atlas Venture

Chelsea Johnson

Principal at Atlas Venture

David Grayzel

Partner at Atlas Venture

Dmitry Balyasny

General Partner at Atlas Venture

Jason Rhodes

Partner at Atlas Venture

Jean-Francois Formela

General Partner at Atlas Venture

Jean-François Formela

Partner at Atlas Venture

Network1

Meridith UngerMentee

Harvard Business School · Kauffman Fellow (Class 15)

Investors connected to Peter in public investor directories — a warm-intro map.

Frequently asked questions

Who is Peter Barrett?: Peter Barrett has worked at Atlas Venture since 2002, helping create therapeutic and drug discovery platform companies. Before Atlas, he co-founded Celera Genomics, serving as executive vice president and chief business officer, and previously held senior management roles at Applera. He holds a BS in chemistry from Lowell Technological Institute (now UMass Lowell) and a PhD in analytical chemistry from Northeastern University.
Where does Peter Barrett work?: Peter Barrett is Co-founder & Board Member of Obsidiantx and Partner at Atlas Venture and Board director at Synlogic and Board director at Mnemosyne Pharmaceuticals.
What does Peter Barrett invest in?: Peter Barrett invests in Biotech.
What check size does Peter Barrett write?: Peter Barrett typically writes checks of $500K – $5M.
What companies did Peter Barrett found?: Peter Barrett founded Obsidiantx.
What boards does Peter Barrett sit on?: Peter Barrett holds tracked board seats at Alnylam, Antegrin Therapeutics, Archemix, Cadent Therapeutics, Harbour Antibodies, Larimar Therapeutics, Momenta, Novamed, Nucleate Bio, Obsidian Therapeutics.
What companies has Peter Barrett invested in?: Investments tracked here include Archemix, Cadent Therapeutics, Deepscale, Harbour Antibodies, Indalo Therapeutics, Infacare Pharmaceutical, JenaValve Technology, Larimar Therapeutics, Momenta Pharmaceuticals, Obsidian Therapeutics, Posterous, Raze Therapeutics, and 2 more.
Where did Peter Barrett go to school?: Peter Barrett studied at Northeastern University (Phd, Analytical Chemistry).